Minnesotans with diabetes will pay no more than $35 monthly for Eli Lilly’s brand-name insulin products, at least for the next five years, under a settlement announced Wednesday by state Attorney General Keith Ellison.
The state in 2018 was the first in the country to sue insulin manufacturers over price-gouging allegations — driven by stories such as the death of Alec Smith, the 26-year-old with Type 1 diabetes who had been rationing medication that he couldn’t afford. His mother, Nicole Smith-Holt, joined Ellison at the State Capitol to announce the deal, saying, “It’s going to save so many lives.”
“It’s been 20 years they have been taking advantage of Type 1 diabetics, Type 2 diabetics,” she said of the drug companies, “taking advantage of the fact that they have to have this product in order to live.”
Minnesota is still suing Novo Nordisk and Sanofi, two other manufacturers of synthetic insulin, but Ellison said he hopes to reach similar terms with them soon to make their versions affordable. New York had reached similar terms last year with all three manufacturers, which also announced they were slashing list prices for insulin at the start of 2024.
The settlement comes amid a continued surge in diabetes, a disease in which the body can’t produce insulin, or produces too little to regulate the body’s blood sugar levels. Minnesota’s adult diabetes rate surpassed 10% for the first time in 2022, according to federal survey data.
The chronic disease can cause heart, kidney and nerve problems, and costs Minnesota around $5 billion each year in medical expenses and lost productivity.
“This comes not a moment too soon,” said Ellison of the settlement, adding that “no one should have to choose between affording their lives and affording to live.”
Eli Lilly in a statement said the settlement “fully resolves one of the longest-running insulin pricing lawsuits and reinforces our commitment to ensuring that Minnesotans have affordable access to Lilly’s insulins. The agreement builds on our longstanding ... efforts to close gaps in the U.S. healthcare system and expand access to affordable insulin.”